Drugs can have different biological effects on humans, not all of them are beneficial. Aripiprazole is a partial dopamine agonist that utilizes antidepressant properties for the treatment of biopolar disorder, clinical depression, schizophrenia and others. This psychotropic drug was developed by Otsuka in Japan and has been marketed as Abilify.
In 2002 Abilify was approved by FDA in the USA and in 2004 by the European Medicines Agency for treatment of schizophrenia. In 2004 the FDA expands the use of drug to treat biopolar disorder and later that year orders label change that describes the risk of hyperglycemia and diabetes in patients taking atypical antipsychotics which included Abilify. In 2006 the drug receives a black box warning stating that it increases the risk of death in elderly users. A year later it gets a black box warning concerning the risk of suicide for patients under the age of 24.